AIMLogo.jpg
AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
May 03, 2021 07:30 ET | AIM ImmunoTech Inc.
OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’ video interview with...
AIMLogo.jpg
AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
April 27, 2021 07:15 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety,...
AIMLogo.jpg
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
April 07, 2021 09:15 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s...
AIMLogo.jpg
AIM ImmunoTech Reports 2020 Year-End Financial Results
March 31, 2021 09:15 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update. 2020...
AIMLogo.jpg
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with COVID-19
March 22, 2021 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center...
AIM ImmunoTech LOGO.jpg
AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th
March 11, 2021 07:00 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be...
AIMLogo.jpg
AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
March 10, 2021 06:55 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM’s Chief Executive Officer, has been invited to present at the...
AIMLogo.jpg
AIM ImmunoTech宣布第1期鼻内安普利近临床研究的首批健康受试者已用药
March 08, 2021 09:15 ET | AIM ImmunoTech Inc.
美国佛罗里达州奥卡拉, March 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.(纽交所代码:AIM)今天宣布已给第1期临床研究的首批健康受试者用药,以研究AIM的药物安普利近(Ampligen)作为一种潜在鼻内疗法的安全性。AIM的目标是开发安普利近,将其作为一种新冠病毒和其他呼吸道病毒性疾病的鼻内预防或早期治疗药物。 ...
AIMLogo.jpg
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study
March 08, 2021 09:15 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of...
AIMLogo.jpg
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
March 04, 2021 06:50 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the...